FDA Approves First Biologic for Kids with Eczema

The subcutaneous injection is intended for patients 6 months to 5 years affected by atopic dermatitis.

Sanofi
Sanofi

Atopic dermatitis, aka eczema, affects more than 10% of Americans of all ages. It’s characterized by inflammation that causes dry, itchy patches on the skin. Though not life-threatening, it can be a painful nuisance and lead to dermal infections. According to a recent Everyday Health article, the FDA just approved the first biologic intended to treat the condition in kids ages 6 months to 5 years.

Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report